Loading...
Market
What will be the primary benefit reported in the next Mayo Clinic study on CAR-T cell therapy for liver cancer by March 2025?
2
Resolution / Starting Odds
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%
Mayo Clinic study publications
Story
Mayo Clinic Advances CAR-T Cell Therapy for Liver Cancer, Secondary Cancer Rate at 6.5%
Sep 19, 2024, 07:03 AM
Researchers at Mayo Clinic are pioneering the use of engineered viruses combined with chimeric antigen receptor T-cell therapy (CAR-T cell therapy) for a multipronged attack on liver cancer. CAR-T cell therapy harnesses the power of a person's immune system to combat cancer cells. Advances in the management of CAR T-cell therapy–related cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) have improved the safety and feasibility of outpatient axi-cel and brexu-cel administration for patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). A new study found that the secondary cancer rate of patients who had received CAR T-cell therapy was approximately 6.5%, lower than some had anticipated. Immunotherapy is being highlighted as a major breakthrough in treating cancer, offering hope in reducing the heavy death toll cancer still delivers, which accounted for 21% of all deaths in 2019.
View original story
Similar markets
Complete remission • 25%
Partial remission • 25%
No change • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%
Significant tumor shrinkage • 25%
Improved survival rates • 25%
No significant effect • 25%
Other • 25%
Yes • 50%
No • 50%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Lifespan Extension • 25%
Cancer Reduction • 25%
Gray Hair Reduction • 25%
Other • 25%
Yes • 50%
No • 50%
Successful with significant results • 25%
Moderate success with some positive results • 25%
No significant results • 25%
Trial halted or inconclusive • 25%
Successful reduction in serum TTR levels • 25%
High adverse events lead to study halt • 25%
Modifications required for safety • 25%
Study continuation without major issues • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%